---
schema_version: "secwatch.filing_event.v1"
accession: "0001759138-26-000030"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2026-06-03T11:02:06+00:00"
generated_at: "2026-06-03T11:05:32.977707+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio reports positive rese-cel data at EULAR; registrational plans for SSc, DM/ASyS, JDM updated

## Summary
- 83% (5/6) DM patients achieved immunomodulator-free moderate/major TIS response at 16 weeks; all maintained through 1.5 years.
- First two PC-free lupus patients: one achieved deep B cell depletion; PK/PD suggests lowest dose is threshold, enabling potential outpatient use.
- SSc registrational study of ~25 patients with ILD to start 4Q26; primary endpoint FVC at 52 weeks.
- DM/ASyS registrational cohort topline data expected mid-2027; JDM to be included in 2H27 BLA with potential priority review voucher.
- Safety: no ICANS in myositis; 87% SSc patients no/grade1 CRS; 94% SLE preconditioning no/grade1 CRS.

## SEC filing metadata
- accession: 0001759138-26-000030
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2026-06-03T11:02:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000030/0001759138-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000175913826000030/caba-20260603.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759138-26-000030
- JSON: https://secwatch.observer/filing/0001759138-26-000030.json
- Plain text: https://secwatch.observer/filing/0001759138-26-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.